Kurs & Likviditet
|2023-08-10||Halvårsutdelning AZN 9.64|
|2023-02-23||Halvårsutdelning AZN 20.69|
|2022-08-11||Halvårsutdelning AZN 9.49|
|2022-02-24||Halvårsutdelning AZN 18|
|2021-08-12||Halvårsutdelning AZN 7.72|
|2021-02-25||Halvårsutdelning AZN 15.76|
|2020-08-13||Halvårsutdelning AZN 7.87|
|2020-02-27||Halvårsutdelning AZN 18.32|
|2019-08-08||Halvårsutdelning AZN 8.49|
|2019-02-28||Halvårsutdelning AZN 17.46|
|2018-08-09||Halvårsutdelning AZN 7.92|
|2018-02-15||Halvårsutdelning AZN 14.97|
|2017-08-10||Halvårsutdelning AZN 7.4|
|2017-02-16||Halvårsutdelning AZN 16.57|
|2016-08-11||Halvårsutdelning AZN 7.81|
|2016-02-18||Halvårsutdelning AZN 16.26|
|2015-08-13||Halvårsutdelning AZN 7.71|
|2015-02-19||Halvårsutdelning AZN 15.62|
|2014-08-13||Halvårsutdelning AZN 6.2|
|2014-02-19||Halvårsutdelning AZN 12.41|
|2013-08-14||Halvårsutdelning AZN 5.92|
|2013-08-01||Analytiker möte 2013|
|2013-02-13||Halvårsutdelning AZN 12.08|
|2012-10-25||Analytiker möte 2012|
|2012-08-08||Halvårsutdelning AZN 6.26|
|2012-02-15||Halvårsutdelning AZN 13.21|
|2011-08-03||Halvårsutdelning AZN 5.33|
|2011-02-02||Halvårsutdelning AZN 11.99|
|2010-08-04||Halvårsutdelning AZN 5.12|
|2010-02-03||Halvårsutdelning AZN 12.43|
|2009-08-05||Halvårsutdelning AZN 4.41|
|2009-02-04||Halvårsutdelning AZN 12.02|
|2008-08-06||Halvårsutdelning AZN 3.34|
|2008-02-06||Halvårsutdelning AZN 8.61|
|2007-08-08||Halvårsutdelning AZN 3.49|
|2007-02-07||Halvårsutdelning AZN 8.6|
|2006-08-09||Halvårsutdelning AZN 3.6|
|2006-02-08||Halvårsutdelning AZN 7.02|
|2005-08-10||Halvårsutdelning AZN 2.99|
|2005-02-09||Halvårsutdelning AZN 4.497|
|2004-08-11||Halvårsutdelning AZN 2.2|
|2004-02-18||Halvårsutdelning AZN 3.91|
|2003-08-20||Halvårsutdelning AZN 2.07|
|2003-02-19||Halvårsutdelning AZN 3.99|
|2002-08-21||Halvårsutdelning AZN 2.21|
|2002-02-20||Halvårsutdelning AZN 5.01|
|2001-08-22||Halvårsutdelning AZN 2.44|
|2001-02-21||Halvårsutdelning AZN 4.49|
|2000-09-04||Halvårsutdelning AZN 2.1|
|2000-03-08||Halvårsutdelning AZN 4.01|
|1999-09-06||Halvårsutdelning AZN 1.89|
|1999-04-01||Split AZN 1:0.5045|
|1997-05-26||Split AZN 1:2|
|1993-06-14||Split AZN 1:5|
|1987-06-04||Split AZN 1:2|
|Lista||Large Cap Stockholm|
|Industri||Läkemedel & Handel|
Treatment with adjuvant Tagrisso reduced the risk of death by more than half.
Positive results from the ADAURA Phase III trial showed AstraZeneca's Tagrisso (osimertinib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumour resection with curative intent.
These results will be presented today in an oral presentation during the Plenary Session at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (abstract #LBA3).
Tagrisso reduced the risk of death by 51% compared to placebo in both the primary analysis population (Stages II-IIIA) (21% data maturity, OS hazard ratio [HR] of 0.49; 95.03% confidence interval [CI] 0.33-0.73; p=0.0004), and in the overall trial population (Stages IB-IIIA) (18% data maturity, OS HR of 0.49; 95.03% CI 0.34-0.70; p<0.0001).
In the primary analysis population, an estimated 85% of patients treated with Tagrisso were alive at five years compared to 73% on placebo. In the overall trial population, an estimated 88% of patients treated with Tagrisso were alive at five years compared to 78% on placebo. Median OS was not yet reached in either population or treatment group. Patients on placebo that recurred with metastatic disease had the opportunity to receive Tagrisso as a subsequent treatment.
Roy S. Herbst, MD, PhD, Deputy Director and Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital, New Haven, Connecticut, US, and principal investigator in the trial, said: "These highly anticipated overall survival results, with 88 per cent of patients alive at five years, are a momentous achievement in the treatment of early-stage EGFR-mutated lung cancer. These data underscore that adjuvant treatment with osimertinib provides patients with the best chance of long-term survival."
Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: "Tagrisso cut the risk of death by more than half in the adjuvant setting, further establishing this transformative medicine as the backbone treatment for EGFR-mutated lung cancer. These results emphasise the importance of diagnosing patients with lung cancer early, testing for EGFR mutations and treating all those with an EGFR mutation with Tagrisso."
Summary of OS results: ADAURA[i]
Stages II-IIIA (primary population) (n=233) (n=237)
Median OS (in months) Not reached Not reached
Hazard ratio (95.03% CI) 0.49 (0.33-0.73)
OS rate (%) (five years) (95% CI) 85 (79-89) 73 (66-78)
Stage IB-IIIA (overall population) (n=339) (n=343)
Median OS (in months) Not reached Not reached
Hazard ratio (95.03% CI) 0.49 (0.34-0.70)
OS rate (%) (five years) (95% CI) 88 (83-91) 78 (73-82)
i The data cut-off date was 27 January, 2023.
At the previously reported disease-free survival analysis, all patients had completed or discontinued treatment. The safety and tolerability of Tagrisso with extended follow-up were consistent with its established profile and previous analyses with no new safety concerns reported. Adverse events at Grade 3 or higher from all causes occurred in 23% of patients in the Tagrisso arm versus 14% in the placebo arm.
Lung cancer is the leading cause of cancer death among both men and women, accounting for about one-fifth of all cancer deaths. Lung cancer is broadly split into NSCLC and small cell lung cancer.[ ]Each year there are an estimated 2.2 million people diagnosed with lung cancer globally with 80-85% of patients diagnosed with NSCLC, the most common form of lung cancer.[1-3][ ]The majority of all NSCLC patients are diagnosed with advanced disease while approximately 25-30% present with resectable disease at diagnosis.[4-5] Early-stage lung cancer diagnoses are often only made when the cancer is found on imaging for an unrelated condition.[6-]
For patients with resectable tumours, the majority eventually develop recurrence despite complete tumour resection and adjuvant chemotherapy. Further, 73% of patients with Stage IB and 56-65% of patients with Stage II disease will survive for five years. This decreases to 41% for patients with Stage IIIA, reflecting a high unmet medical need. Approximately 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia have EGFRm NSCLC.[10-12 ]These patients are particularly sensitive to treatment with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) which block the cell-signalling pathways that drive the growth of tumour cells.
ADAURA was a randomised, double-blind, placebo-controlled, global Phase III trial in the adjuvant treatment of 682 patients with Stage IB, II, IIIA EGFRm NSCLC following complete tumour resection and, at physicians' and patients' discretion, adjuvant chemotherapy. Patients were treated with Tagrisso 80mg once-daily oral tablets or placebo for three years or until disease recurrence.
The trial was enrolled in more than 200 centres across more than 20 countries, including the US, Europe, South America, Asia and the Middle East. The primary endpoint was DFS in Stage II and IIIA patients and key secondary endpoints included DFS in Stage IB, II and IIIA patients, and OS in both the primary and overall populations.
Though the primary data readout was originally anticipated in 2022, data from the trial were reported early (https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-phase-iii-adaura-trial-will-be-unblinded-early-after-overwhelming-efficacy-in-the-adjuvant-treatment-of-patients-with-egfr-mutated-lung-cancer.html) following a recommendation from an Independent Data Monitoring Committee based on its determination of overwhelming efficacy.
In May 2020 (https://www.astrazeneca.com/media-centre/press-releases/2020/tagrisso-demonstrated-unprecedented-disease-free-survival-in-the-adjuvant-treatment-of-stage-ib-iiia-patients-with-egfr-mutated-lung-cancer.html), AstraZeneca announced Tagrisso demonstrated a statistically significant and clinically meaningful improvement in DFS in this setting. In September 2022 (https://www.astrazeneca.com/media-centre/press-releases/2022/tagrisso-demonstrated-5-year-median-disease-free-survival-in-the-adjuvant-treatment-of-patients-with-egfr-mutated-lung-cancer.html), updated results demonstrated a median DFS of nearly five and a half years.
Tagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases. Tagrisso (40mg and 80mg once-daily oral tablets) has been used to treat nearly 700,000 patients across its indications worldwide and AstraZeneca continues to explore Tagrisso as a treatment for patients across multiple stages of EGFRm NSCLC.
Tagrisso is approved as monotherapy in more than 100 countries including in the US, EU, China and Japan. These include for 1st-line treatment of patients with locally advanced or metastatic EGFRm NSCLC, locally advanced or metastatic EGFR T790M mutation-positive NSCLC, and adjuvant treatment of early-stage (IB, II and IIIA) EGFRm NSCLC.
In May, Tagrisso demonstrated clinical benefit in combination with chemotherapy in the FLAURA2 Phase III trial in advanced EGFRm NSCLC.
In Phase III trials, Tagrisso is being tested in the neoadjuvant resectable setting (NeoADAURA), in the Stage IA2-IA3 adjuvant resectable setting (ADAURA2) and in the Stage III locally advanced unresectable setting (LAURA). AstraZeneca is also researching ways to address tumour mechanisms of resistance through the SAVANNAH and ORCHARD Phase II trials, and the SAFFRON Phase III trial, which test Tagrisso given concomitantly with savolitinib, an oral, potent and highly selective MET-TKI, as well as other potential new medicines.
AstraZeneca in lung cancer
AstraZeneca is working to bring patients with lung cancer closer to cure through the detection and treatment of early-stage disease, while also pushing the boundaries of science to improve outcomes in the resistant and advanced settings. By defining new therapeutic targets and investigating innovative approaches, the Company aims to match medicines to the patients who can benefit most.
The Company's comprehensive portfolio includes leading lung cancer medicines and the next wave of innovations, including Tagrisso and Iressa (gefitinib); Imfinzi (durvalumab) and Imjudo (tremelimumab); Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan in collaboration with Daiichi Sankyo; Orpathys (savolitinib) in collaboration with HUTCHMED; as well as a pipeline of potential new medicines and combinations across diverse mechanisms of action.
AstraZeneca is a founding member of the Lung Ambition Alliance, a global coalition working to accelerate innovation and deliver meaningful improvements for people with lung cancer, including and beyond treatment.
AstraZeneca in oncology
AstraZeneca is leading a revolution in oncology with the ambition to provide cures for cancer in every form, following the science to understand cancer and all its complexities to discover, develop and deliver life-changing medicines to patients.
The Company's focus is on some of the most challenging cancers. It is through persistent innovation that AstraZeneca has built one of the most diverse portfolios and pipelines in the industry, with the potential to catalyse changes in the practice of medicine and transform the patient experience.
AstraZeneca has the vision to redefine cancer care and, one day, eliminate cancer as a cause of death.
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com (http://www.astrazeneca.com/) and follow the Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca).
For details on how to contact the Investor Relations Team, please click here (https://www.astrazeneca.com/investor-relations.html#Contacts). For Media contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html).
1. World Health Organisation. International Agency for Research on Cancer. Lung Fact Sheet. Available at https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed May 2023.
2. LUNGevity Foundation. Types of Lung Cancer. Available at https://lungevity.org/for-patients-caregivers/lung-cancer-101/types-of-lung-cancer. Accessed May 2023.
3. Cheema PK, et al. Perspectives on treatment advances for stage III locally advanced unresectable non-small-cell lung cancer. Curr Oncol. 2019;26(1):37-42.
4. Cagle P, et al. Lung Cancer Biomarkers: Present Status and Future Developments. Archives Pathology Lab Med. 2013;137:1191-1198.
5. Le Chevalier T, et al. Adjuvant Chemotherapy for Resectable Non-Small-Cell Lung Cancer: Where is it Going? Ann Oncol. 2010;21:vii196-vii198.
6. Sethi S, et al. Incidental Nodule Management - Should There Be a Formal Process? J Thorac Oncol. 2016:8;S494-S497.
7. LUNGevity Foundation. Screening and Early Detection. Available at https://lungevity.org/for-patients-caregivers/lung-cancer-101/screening-early-detection. Accessed March 2023.
8. Pignon JP, et al. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552-3559.
9. Goldstraw P, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39-51.
10. Szumera-Ciećkiewicz A, et al. EGFR Mutation Testing on Cytological and Histological Samples in Non-Small Cell Lung Cancer: a Polish, Single Institution Study and Systematic Review of European Incidence. Int J Clin Exp Pathol. 2013:6;2800-12.
11. Keedy VL, et al. American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal
Growth Factor Receptor (EGFR) Mutation Testing for Patients with Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy. J Clin Oncol. 2011:29;2121-27.
12. Ellison G, et al. EGFR Mutation Testing in Lung Cancer: a Review of Available Methods and Their Use for Analysis of Tumour Tissue and Cytology Samples. J Clin Pathol. 2013:66;79-89.
13. Cross DA, et al. AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer. Cancer Discov. 2014;4(9):1046-1061.